Company Information

  

Address: 2200 PENNSYLVANIA AVE NW
SUITE 300E 
City: WASHINGTON 
State: DC 
Zip Code: 20037 
Telephone: 202-734-3400 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Vanda Pharmaceuticals Inc. (we or Vanda ) is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. Vanda commenced its operations in 2003 and our product portfolio includes: * HETLIOZĀ® (tasimelteon), a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24), was approved by the U.S. Food and Drug Administration (FDA) in January 2014 and launched commercially in the U.S. in April 2014. In July 2015, the European Commission (EC) granted centralized marketing authorization with unified labeling for HETLIOZĀ® for the treatment of Non-24 in totally blind adults. HETLIOZĀ® was commercially launched in Germany in August 2016.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-0.23NAN/E
03/2017-0.29NAN/E
12/2016-0.41NAN/E
09/2016-0.25NAN/E
06/2016-0.47NAN/E
03/2016-0.50NAN/E
12/2015-0.94NAN/E
09/20151.44NA7.83

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.04Total Liab/Total Assets0.38
Net Inc/Total Assets-0.09Total Liab/Inv Cap0.49
Net Inc/Inv Cap-0.11Total Liab/Comm Equity0.17
Pretax Inc/Net Sales-0.12Interest Coverage RatioNA
Net Inc/Net Sales-0.12Curr Debt/EquityNA
Cash Flow/Net Sales-0.06LTD/Equity0.19
SG&A/NetSales0.68Total Debt/Equity0.19
Asset Utilization   Liquidity  
Net Receivables Turnover7.98Quick Ratio3.45
Inventory Turnover23.84Current Ratio3.46
Inventory Day Sales0.09Net Rec/Curr Assets0.12
Net Sales/Work Cap1.18Inv/Curr Assets0.00
Net Sales/PP&E17.42  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 42.06 37.42 38.24 38.48
Cost of Goods Sold 4.53 4.00 5.27 6.99
Selling & Admin Exps 31.37 30.30 23.91 21.91
Operating Income -1.92 -7.91 -0.65 -0.65
Interest Exp NA NA NA NA
Pretax Income -1.53 -7.63 -0.50 -0.43
Other Income 0.40 0.28 0.15 0.22
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -1.53 -7.65 -0.60 -0.43

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 137.12 137.76 141.34 142.58
Receivables - Total 21.02 17.75 20.27 15.93
Inventories - Total 0.74 0.82 0.78 0.87
Total Current Assets 174.61 168.56 174.18 170.41
Net Property, Plant & Equipment 9.13 8.79 8.38 8.11
Total Assets 210.67 204.72 210.37 208.44
Liabilities        
Accounts Payable 50.44 47.97 50.32 50.68
Debt in Current Liabilities 25.00 25.00 NA NA
Total Current Liabilities 75.44 72.97 50.32 50.68
Long-Term Debt 0.00 0.00 25.00 25.00
Total Liabilities 79.25 76.58 79.04 79.28
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.05 0.05 0.04 0.04
Retained Earnings -355.04 -353.50 -345.86 -345.26
Treasury Stock NA NA NA NA
Total Stockholders' Equity 131.42 128.14 131.33 129.17
Total Liabilities and Stockholders' Equity 210.67 204.72 210.37 208.44

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -2.26 -5.36 -1.18 1.24
Net Cash Provided by Investing Activities -5.83 -17.17 8.09 2.37
Net Cash Provided by Financing Activities 2.19 2.21 0.75 5.96

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/201232.73-28.62-0.98
12/201333.88-21.06-0.67
12/201450.1620.190.55
12/2015109.92-39.86-0.94
12/2016146.02-18.01-0.41
Growth Rates45.34----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/1714838,77886.45




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.